Showing results (1-10 of 131) with videos related to
Sort By:
Pageof 14
Current Opinion in Lipidology|October 3, 2019
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?Michael B Boffa, Marlys L KoschinskyAtherosclerosis|May 23, 2022
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiologyMarlys L Koschinsky, Michael B BoffaThe Biochemical Journal|September 20, 2024
Lipoprotein(a) and cardiovascular diseaseMichael B Boffa, Marlys L KoschinskyCurrent Opinion in Lipidology|June 13, 2022
Understanding the ins and outs of lipoprotein (a) metabolismMichael B Boffa, Marlys L KoschinskyNature Reviews. Cardiology|January 25, 2019
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular diseaseMichael B Boffa, Marlys L KoschinskyCurrent Atherosclerosis Reports|August 31, 2013
Update on lipoprotein(a) as a cardiovascular risk factor and mediatorMichael B Boffa, Marlys L KoschinskyCurrent Cardiology Reports|September 24, 2013
Screening for and management of elevated Lp(a)Michael B Boffa, Marlys L KoschinskyEndocrinology and Metabolism Clinics of North America|November 30, 2014
Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrumMarlys L Koschinsky, Michael B BoffaArteriosclerosis, Thrombosis, and Vascular Biology|August 7, 2025
Lp(a) as a Risk Factor for Peripheral Artery Disease: Context Is EverythingMarlys L Koschinsky, Michael B BoffaClinical Biochemistry|March 3, 2007
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological rolesMichael B Boffa, Marlys L KoschinskyPageof 14